Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin + ampicillin/sulbactam versus meropenem + ampicillin/sulbactam for meropenem-resistant Acinetobacter ventilator-associated pneumonia
IRCT20260805070540N1Phase 2Recruiting
- Sponsor
- Babol University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in ventilator-associated pneumonia (VAP) and Healthcare-associated infection (HAI) comparing Colistin + ampicillin/sulbactam with Meropenem + ampicillin/sulbactam (2 arms). Primary endpoints: Clinical improvement and Microbiological clearance. Started Aug 2026; status: recruiting.
02
Drugs
colistinampicillin + sulbactammeropenem
03
Conditions
ventilator-associated pneumonia (VAP)Healthcare-associated infection (HAI)
Beyond the preview
Go deeper on IRCT20260805070540N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260805070540N1.